(NASDAQ: VCEL) Vericel's forecast annual revenue growth rate of 16.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.79%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Vericel's revenue in 2026 is $292,086,000.On average, 10 Wall Street analysts forecast VCEL's revenue for 2026 to be $17,303,958,376, with the lowest VCEL revenue forecast at $16,534,870,862, and the highest VCEL revenue forecast at $17,984,697,855. On average, 10 Wall Street analysts forecast VCEL's revenue for 2027 to be $20,246,509,673, with the lowest VCEL revenue forecast at $19,024,446,977, and the highest VCEL revenue forecast at $21,697,868,713.
In 2028, VCEL is forecast to generate $23,582,286,326 in revenue, with the lowest revenue forecast at $21,540,067,888 and the highest revenue forecast at $26,037,646,728.